-=Teva Pharma (TEVA) reported earnings on Wed 9 Feb 22 (b/o)

 

Teva Pharma beats by $0.04, misses on revs; guides FY22 EPS below consensus, revs below consensus 

• Reports Q4 (Dec) earnings of $0.77 per share, excluding non-recurring items, $0.04 better than the S&P Capital IQ Consensus of $0.73; revenues fell 7.9% year/year to $4.1 bln vs the $4.28 bln S&P Capital IQ Consensus.
• Co issues downside guidance for FY22, sees EPS of $2.40-$2.60, excluding non-recurring items, vs. $2.67 S&P Capital IQ Consensus; sees FY22 revs of $15.6-$16.2 bln vs. $16.29 bln S&P Capital IQ Consensus.
  • "In 2021 Teva delivered solid results, generating strong cash flow and improving our profitability. While COVID-19 continued to impact patient behavior and global prescribing patterns, we continued to optimize our supply chain and manufacturing capabilities to provide essential medicines to the millions of patients who rely on us throughout the world. We improved our gross and operating margin and reduced our net debt, keeping us on our path to achieve our 2023 long-term goals", said Mr. Kre Schultz, Teva's President and CEO. Mr. Schultz continued: "Looking forward to 2022, we expect to see continued growth of our key products AUSTEDO and AJOVY, as well as to continue to advance our core business through the launch of high quality generic medicines around the world. We are also excited about the expected FDA approval and launch of Risperidone LAI, an important treatment for patients suffering from schizophrenia."